Agenus Inc.

1.90-0.0800-4.04%Vol 8.15M1Y Perf -63.67%
Jun 24th, 2022 16:00 DELAYED
BID1.88 ASK1.96
Open1.98 Previous Close1.98
Pre-Market- After-Market1.90
 - -  - -%
Target Price
7.50 
Analyst Rating
Strong Buy 1.00
Potential %
294.74 
Finscreener Ranking
★★★★+     56.87
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★+     48.09
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★+     54.31
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
11.73 
Earnings Rating
Strong Buy
Market Cap537.43M 
Earnings Date
8th Aug 2022
Alpha-0.00 Standard Deviation0.22
Beta1.25 

Today's Price Range

1.842.01

52W Range

1.256.79

5 Year PE Ratio Range

-2.40-3.10

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
21.02%
1 Month
31.03%
3 Months
-29.63%
6 Months
-46.93%
1 Year
-63.67%
3 Years
-37.50%
5 Years
-52.26%
10 Years
-62.52%

TickerPriceChg.Chg.%
AGEN1.90-0.0800-4.04
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
1.60
1.80
0.75
4.09
0.60
Leverage Ratio -10.60
ProfitabilityValueIndustryS&P 500US Markets
26.90
12.90
15.10
-267.50
-8.14
RevenueValueIndustryS&P 500US Markets
309.89M
1.14
29.17
47.57
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.29-0.1934.48
Q04 2021-0.16-0.26-62.50
Q03 20210.460.6950.00
Q02 2021-0.24-0.37-54.17
Q01 2021-0.31-0.2712.90
Q04 2020-0.22-0.209.09
Q03 2020-0.26-0.28-7.69
Q02 2020-0.27-0.28-3.70
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.2317.86Positive
9/2022 QR-0.2516.67Positive
12/2022 FY-0.8921.24Positive
12/2023 FY-0.6428.89Positive
Next Report Date8th Aug 2022
Estimated EPS Next Report-0.23
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume8.15M
Shares Outstanding282.86K
Shares Float268.60M
Trades Count14.38K
Dollar Volume15.51M
Avg. Volume4.92M
Avg. Weekly Volume6.07M
Avg. Monthly Volume4.41M
Avg. Quarterly Volume4.29M

Agenus Inc. (NASDAQ: AGEN) stock closed at 1.9 per share at the end of the most recent trading day (a -4.04% change compared to the prior day closing price) with a volume of 8.15M shares and market capitalization of 537.43M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 328 people. Agenus Inc. CEO is Garo H Armen.

The one-year performance of Agenus Inc. stock is -63.67%, while year-to-date (YTD) performance is -40.99%. AGEN stock has a five-year performance of -52.26%. Its 52-week range is between 1.25 and 6.79, which gives AGEN stock a 52-week price range ratio of 11.73%

Agenus Inc. currently has a PE ratio of -12.10, a price-to-book (PB) ratio of 27.07, a price-to-sale (PS) ratio of 1.37, a price to cashflow ratio of 767.40, a PEG ratio of 2.32, a ROA of -5.67%, a ROC of -90.21% and a ROE of 23.00%. The company’s profit margin is -8.14%, its EBITDA margin is 15.10%, and its revenue ttm is $309.89 Million , which makes it $1.14 revenue per share.

Of the last four earnings reports from Agenus Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.23 for the next earnings report. Agenus Inc.’s next earnings report date is 08th Aug 2022.

The consensus rating of Wall Street analysts for Agenus Inc. is Strong Buy (1), with a target price of $7.5, which is +294.74% compared to the current price. The earnings rating for Agenus Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Agenus Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Agenus Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 22.73, ATR14 : 0.15, CCI20 : 168.75, Chaikin Money Flow : 0.13, MACD : 0.01, Money Flow Index : 58.19, ROC : 13.10, RSI : 59.99, STOCH (14,3) : 85.53, STOCH RSI : 0.84, UO : 63.70, Williams %R : -14.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Agenus Inc. in the last 12-months were: Christine Klaskin (Option Excercise at a value of $55 652), Christine Klaskin (Sold 11 120 shares of value $72 280 ), Christine M. Klaskin (Option Excercise at a value of $55 652), Christine M. Klaskin (Sold 11 120 shares of value $72 280 ), Garo H. Armen (Option Excercise at a value of $400 438), Garo H. Armen (Sold 82 107 shares of value $533 696 ), Steven J. O'Day (Option Excercise at a value of $0), Steven J. O'Day (Sold 38 679 shares of value $118 346 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Agenus Inc.

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.

CEO: Garo H Armen

Telephone: +1 781 674-4400

Address: 3 Forbes Road, Lexington 02421-7305, MA, US

Number of employees: 328

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

68%32%

Bearish Bullish

65%35%

Bearish Bullish

60%40%

News

Stocktwits